Who is sponsoring NCT02221310?

NCT02221310 is sponsored by New York Medical College.

What drugs are being tested in NCT02221310?

Interventions in NCT02221310: Gemtuzumab Ozogamicin.

What condition does NCT02221310 study?

NCT02221310 studies Acute Myelogenous Leukemia, Myelodysplastic Syndrome.

Is NCT02221310 still recruiting?

NCT02221310 is currently completed. Last updated 26 October 2023.

Last reviewed 2023-10-26 · How we verify

NCT02221310

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS

Completed Phase 2 Last updated 26 October 2023

What this trial tests

Phase 2 trial testing Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia in 25 participants. Completed in 4 April 2023.

Timeline

7 December 2011

Primary endpoint
4 April 2023

4 April 2023

Quick facts

Lead sponsor	New York Medical College
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	7 December 2011
Primary completion	4 April 2023
Estimated completion	4 April 2023
Sites	1 location across United States

Drugs / interventions tested

Gemtuzumab Ozogamicin (Gemtuzumab Ozogamicin) — full drug profile →

Conditions studied

Acute Myelogenous Leukemia — all drugs for Acute Myelogenous Leukemia →
Myelodysplastic Syndrome — all drugs for Myelodysplastic Syndrome →

Sponsor

New York Medical College

Who can join

Under 25, any sex, with Acute Myelogenous Leukemia or Myelodysplastic Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Targeted immune therapy with gemtuzumab ozogamicin (Mylotarg) in combination with chemotherapy followed by allogeneic stem cell transplantation will be given to patients with high risk acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Acquired Resistance to Antibody-Drug Conjugates.
Collins DM, Bossenmaier B, Kollmorgen G, Niederfellner G. · · 2019 · cited 109× · PMID 30897808 · DOI 10.3390/cancers11030394
Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.
Ramos NR, Mo CC, Karp JE, Hourigan CS. · · 2015 · cited 91× · PMID 25932335 · DOI 10.3390/jcm4040665
Natural killer cell-based immunotherapy for acute myeloid leukemia.
Xu J, Niu T. · · 2020 · cited 83× · PMID 33287858 · DOI 10.1186/s13045-020-00996-x
Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia.
Yu B, Liu D. · · 2019 · cited 37× · PMID 31695916 · DOI 10.1186/s40364-019-0175-x
Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.
Vacchelli E, Pol J, Bloy N, Eggermont A, et al · · 2015 · cited 32× · PMID 25949870 · DOI 10.4161/2162402x.2014.985940
Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions.
Schürch CM. · · 2018 · cited 30× · PMID 29868474 · DOI 10.3389/fonc.2018.00152
Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment.
Gbolahan OB, Zeidan AM, Stahl M, Abu Zaid M, et al · · 2017 · cited 26× · PMID 28758974 · DOI 10.3390/ijms18081660
Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin.
Gottardi M, Simonetti G, Sperotto A, Nappi D, et al · · 2021 · cited 16× · PMID 34572794 · DOI 10.3390/cancers13184566

Verify or expand the search:

Other trials of Gemtuzumab Ozogamicin

Trials testing the same drug.

NCT06917911 — Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin · Phase 2 · not yet recruiting
NCT05564390 — MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Wi · Phase 2 · recruiting
NCT04915612 — Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patient · Phase 1 · completed
NCT04207190 — Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia · Phase 1 · completed
NCT04293562 — A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed A · Phase 3 · recruiting

Other recruiting trials for Acute Myelogenous Leukemia

Currently open trials in the same condition.

NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06904482 — Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood · Phase 2 · recruiting
NCT06680661 — ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis · Phase 2 · recruiting
NCT06131801 — Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution · recruiting
NCT05974150 — Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia · recruiting

Other New York Medical College trials

Trials by the same sponsor.

NCT06617286 — CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma · Phase 1, PHASE2 · not yet recruiting
NCT07225972 — Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC · Phase 3 · not yet recruiting
NCT07013565 — Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL · Phase 2 · active not recruiting
NCT05987124 — Defibrotide Dose-escalation for SOS Post-HSCT · Phase 2 · recruiting
NCT05564598 — CMV CTLs in Neonates With CMV Infection · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02221310 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by New York Medical College
Last refreshed: 26 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02221310.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing